- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04364204
Hypothermia Prevention in Low Birthweight and Preterm Infants
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the effect of the bracelet on KMC practices and neonatal health outcomes in LBW infants using a randomized controlled trial. Infants currently being treated in the KMC or neonatal wards of the participating hospitals will be screened for eligibility by study nurses. After obtaining parental consent, infants will be randomly assigned with a 1:1 ratio to KMC with and without the BEMPU® bracelet.
A standardized questionnaire will be administered to each mother to collect information on socio-demographic characteristics and contact information. As is the standard of care, all mothers regardless of study arm will be taught how to provide KMC, how to monitor the infant's condition and recognize dangerous clinical signs during KMC and will be supported by a nurse during initial attempts at practicing KMC.
Mothers of infants randomly allocated to the intervention arm will be taught to use the bracelet. The meaning of the audiovisual alarm will be explained as well as the measures to be taken if the device indicates any sign of hypothermia. There will not be any additional training beyond that pertaining to the BEMPU® bracelet. The study nurse will then place the BEMPU® bracelet on the wrist of the infant. Infants in the intervention arm will wear the bracelet for up to 28 days post-discharge.
After discharge, participants in both the intervention and control arms will receive two study visits; one at 7 days post discharge and one at 28 days post-discharge. During each visit, infants will receive a physical examination to collect weight, length, head circumference and axillary temperature, and additional data will be collected on history of illnesses, care-seeking and treatment, KMC and feeding practices, and frequency of use of the bracelet (if applicable).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mufaro Kanyangarara
- Phone Number: 8037777562
- Email: mufaro@mailbox.sc.edu
Study Locations
-
-
-
Accra, Ghana
- Achimota General Hospital
-
Contact:
- Prince Owusu
-
Accra, Ghana
- Greater Accra Regional Hospital
-
Contact:
- Prince Owusu
-
Accra, Ghana
- Korle-Bu Teaching Hospital
-
Contact:
- Prince Owusu
-
Accra, Ghana
- Princess Marie Luis Children's Hospital
-
Contact:
- Prince Owusu
-
Cape Coast, Ghana
- Central Regional Hospital
-
Contact:
- Prince Owusu
-
Koforidua, Ghana
- Eastern Regional Hospital
-
Contact:
- Prince Owusu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Currently being treated in the KMC or neonatal ward at one of the participating hospitals
- Age<28 days
- Weight <2,500 grams at birth
- Clinically stable
- Mother is available, willing and able to provide consent
Exclusion Criteria:
- Clinically unstable
- Twin or multiple birth
- Ineligible to initiate KMC
- Mother <18 years of age
- Residence outside health facility catchment area or intention to relocate during the four weeks following discharge
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Kangaroo mother care with bracelet
|
Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital.
The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C,
signaling hypothermia and prompting caregiver to provide thermal care.
|
|
Active Comparator: Kangaroo mother care
|
Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital.
This is the current standard of care for low birthweight/preterm infants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hypothermia
Time Frame: up to 28 days
|
Axilliary temperature <36.5 degrees Celsius assessed at 7 days
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight gain
Time Frame: 7 days and 28 days
|
Change in weight in grams assessed at 7 days and 28 days
|
7 days and 28 days
|
|
Kangaroo Mother Care
Time Frame: 7 days and 28 days
|
Proportion of babies who received KMC for at least 8 hours in the last 24 hours assessed at 7 days and 28 days
|
7 days and 28 days
|
|
All cause mortality
Time Frame: 28 days
|
Number of neonatal deaths
|
28 days
|
|
Exclusive breastfeeding
Time Frame: 7 days and 28 days
|
Proportion of babies who were exclusively breastfed in the last 24 hours assessed at 7 days and 28 days
|
7 days and 28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mufaro Kanyangarara, University of South Carolina
- Principal Investigator: Prince Owusu, Centre for Learning and Childhood Development - Ghana
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00095600
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.